Works matching DE "MOLNUPIRAVIR"
Results: 195
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study.
- Published in:
- Respiratory Research, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s12931-025-03156-2
- By:
- Publication type:
- Article
Reaktionskaskaden evolvierter Enzyme zur Synthese komplexer Moleküle.
- Published in:
- Angewandte Chemie, 2022, v. 134, n. 39, p. 1, doi. 10.1002/ange.202208358
- By:
- Publication type:
- Article
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries.
- Published in:
- Pathogens & Global Health, 2023, v. 117, n. 6, p. 525, doi. 10.1080/20477724.2023.2232593
- By:
- Publication type:
- Article
Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis.
- Published in:
- Animals (2076-2615), 2024, v. 14, n. 9, p. 1322, doi. 10.3390/ani14091322
- By:
- Publication type:
- Article
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 5, p. 605, doi. 10.1007/s40273-023-01263-w
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 7, p. 699, doi. 10.1007/s40273-022-01168-0
- By:
- Publication type:
- Article
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence.
- Published in:
- Infectious Disease Reports, 2023, v. 15, n. 6, p. 662, doi. 10.3390/idr15060061
- By:
- Publication type:
- Article
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert).
- Published in:
- 2024
- By:
- Publication type:
- Letter
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2, Update Alert).
- Published in:
- 2024
- By:
- Publication type:
- Letter
In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir–ritonavir improved outcomes.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 1, p. JC7, doi. 10.7326/J23-0108
- By:
- Publication type:
- Article
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 10, p. 1, doi. 10.7326/L23-0265
- By:
- Publication type:
- Article
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 10, p. 1, doi. 10.7326/L23-0264
- By:
- Publication type:
- Article
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 6, p. 807, doi. 10.7326/M22-3565
- By:
- Publication type:
- Article
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19: A Target Trial Emulation Study.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 4, p. 505, doi. 10.7326/M22-3057
- By:
- Publication type:
- Article
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
- Published in:
- Annals of Internal Medicine, 2022, v. 175, n. 8, p. 1126, doi. 10.7326/M22-0729
- By:
- Publication type:
- Article
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
- Published in:
- Annals of Internal Medicine, 2022, v. 175, n. 4, p. JC40, doi. 10.7326/J22-0017
- By:
- Publication type:
- Article
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
- Published in:
- Annals of Medicine, 2022, v. 54, n. 1, p. 516, doi. 10.1080/07853890.2022.2034936
- By:
- Publication type:
- Article
Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study.
- Published in:
- Journal of Infection in Developing Countries, 2024, v. 18, n. 5, p. 694, doi. 10.3855/jidc.18802
- By:
- Publication type:
- Article
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 6, p. 1380, doi. 10.1093/infdis/jiae213
- By:
- Publication type:
- Article
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 12, p. 1667, doi. 10.1093/infdis/jiad324
- By:
- Publication type:
- Article
Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 8, p. 1033, doi. 10.1093/infdis/jiad195
- By:
- Publication type:
- Article
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 5, p. 591, doi. 10.1093/infdis/jiad058
- By:
- Publication type:
- Article
Oxidative DNA damage by N4-hydroxycytidine, a metabolite of the SARS-CoV-2 antiviral molnupiravir.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model.
- Published in:
- 2021
- By:
- Publication type:
- journal article
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Erratum.
- Published in:
- 2023
- Publication type:
- Correction Notice
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19.
- Published in:
- Biotechnology Letters, 2022, v. 44, n. 7, p. 831, doi. 10.1007/s10529-022-03259-6
- By:
- Publication type:
- Article
Evaluation of the mutagenic effects of Molnupiravir and N4‐hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
- Published in:
- Environmental & Molecular Mutagenesis, 2022, v. 63, n. 7, p. 320, doi. 10.1002/em.22510
- By:
- Publication type:
- Article
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
- Published in:
- Environmental & Molecular Mutagenesis, 2022, v. 63, n. 1, p. 37, doi. 10.1002/em.22471
- By:
- Publication type:
- Article
Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir.
- Published in:
- Toxicological Sciences, 2024, v. 202, n. 2, p. 278, doi. 10.1093/toxsci/kfae112
- By:
- Publication type:
- Article
Omicron COVID-19 - A Variant of Concern for the Health Care workers.
- Published in:
- Indian Practitioner, 2022, v. 75, n. 1, p. 7
- By:
- Publication type:
- Article
Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 8, p. 2303, doi. 10.3390/jcm13082303
- By:
- Publication type:
- Article
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 1, p. 34, doi. 10.3390/jcm12010034
- By:
- Publication type:
- Article
Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 21, p. 6464, doi. 10.3390/jcm11216464
- By:
- Publication type:
- Article
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study.
- Published in:
- Journal of Pharmaceutical Health Care & Sciences, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40780-024-00376-4
- By:
- Publication type:
- Article
A Green Voltammetric Determination of Molnupiravir Using a Disposable Screen-Printed Reduced Graphene Oxide Electrode: Application for Pharmaceutical Dosage and Biological Fluid Forms.
- Published in:
- Chemosensors, 2023, v. 11, n. 9, p. 471, doi. 10.3390/chemosensors11090471
- By:
- Publication type:
- Article
Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma.
- Published in:
- Biomedicines, 2023, v. 11, n. 9, p. 2356, doi. 10.3390/biomedicines11092356
- By:
- Publication type:
- Article
Emerging small-molecule antiviral agents in long COVID prevention.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1457672
- By:
- Publication type:
- Article
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong.
- Published in:
- Emerging Infectious Diseases, 2024, v. 30, n. 1, p. 70, doi. 10.3201/eid3001.230414
- By:
- Publication type:
- Article
Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience.
- Published in:
- Transplant International, 2024, p. 1, doi. 10.3389/ti.2024.12920
- By:
- Publication type:
- Article
Can Tremor Be a Rare Side Effect Related to Molnupiravir?
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 289, doi. 10.4274/mjima.galenos.2022.2022.38
- By:
- Publication type:
- Article
HPLC/UV approach method for the first simultaneous estimation of molnupiravir and ertapenem as a binary mixture in human plasma and dosage form as a regimen for COVID-19 treatments.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-01024-y
- By:
- Publication type:
- Article
HPLC/UV approach method for the first simultaneous estimation of molnupiravir and ertapenem as a binary mixture in human plasma and dosage form as a regimen for COVID-19 treatments.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-01024-y
- By:
- Publication type:
- Article
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
- Published in:
- Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-04322-8
- By:
- Publication type:
- Article
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
- Published in:
- Bulletin of the National Research Centre, 2022, v. 46, n. 1, p. 1, doi. 10.1186/s42269-022-00753-9
- By:
- Publication type:
- Article
Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study From the Czech Republic.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 12, p. 1, doi. 10.1093/ofid/ofae685
- By:
- Publication type:
- Article
Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 10, p. 1, doi. 10.1093/ofid/ofac527
- By:
- Publication type:
- Article
DFT and Molecular Docking Studies of an Antiviral Drug: Molnupiravir.
- Published in:
- Indian Journal of Pure & Applied Physics, 2023, v. 61, n. 9, p. 810, doi. 10.56042/ijpap.v61i9.3125
- By:
- Publication type:
- Article
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-53862-y
- By:
- Publication type:
- Article